Quintiles to provide clinical services to Solvay

23-Jul-2001

Quintiles Transnational Corp has signed an agreement with Solvay Pharmaceuticals that establishes a long-term relationship under which Quintiles will provide a substantial portion of Solvay's clinical development services. Under the five-year agreement, Quintiles is expected to provide at least 40 per cent of Solvay's outsourced clinical projects in year one and a minimum of 50 per cent of Solvay's outsourced clinical projects over the following four years. Solvay intends to use Quintiles as a preferred provider over this initial five-year period. This non-exclusive agreement is effective immediately and is anticipated to generate significant revenues for Quintiles, dependent on the progress of Solvay's research and development portfolio and other factors. The agreement follows a previously announced initiative by Solvay to refocus selected elements of the company's research and development work to specialized, highly skilled external partners with the expertise and flexibility to enhance Solvay's drug development efforts. "We are pleased to sign this preferred provider agreement with Quintiles," said Dr. Werner Cautreels, Solvay Pharmaceuticals head of global research and development. "Working with Quintiles raises our ability to progress our portfolio optimally and shorten development times. Their experience, skills, dedicated cutting-edge information technology capabilities and global network makes them a preferred provider of clinical trial services to us. Accessing their strong skills base complements and accelerates our ability to add value to our portfolio faster." Under this agreement, Quintiles will provide a wide range of global services including clinical monitoring, data management, biostatistics, quality assurance and patient recruitment as well as clinical trial supply services and central laboratory services.

https://www.chemeurope.com/en/news/4014/quintiles-to-provide-clinical-services-to-solvay.html